United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - micrurus corallinus venom (unii: v0s6h36980) (micrurus corallinus venom - unii:v0s6h36980), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), arsenic triiodide (unii: 3029988o2t) (arsenic cation (3+) - unii:c96613f5av), gold (unii: 79y1949pyo) (gold - unii:79y1949pyo), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), selenicereus grandiflorus stem (unii: 7114sv0myk) (selenicereus grandiflor - micrurus corallinus venom 30 [hp_x] in 1 ml - hypertension     formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.                              formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - micrurus corallinus venom (unii: v0s6h36980) (micrurus corallinus venom - unii:v0s6h36980), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), arsenic triiodide (unii: 3029988o2t) (arsenic cation (3+) - unii:c96613f5av), gold (unii: 79y1949pyo) (gold - unii:79y1949pyo), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), selenicereus grandiflorus stem (unii: 7114sv0myk) (selenicereus grandiflor - micrurus corallinus venom 30 [hp_x] in 1 g - hypertension     formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.                              formulated for symptoms including headache, elevated b/p readings, tinnitus, anxiety, depression, sweating, pallor and nausea.

United States - English - NLM (National Library of Medicine)

hd supply facilities maintenance, ltd - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) -

European Union - English - EMA (European Medicines Agency)

linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - calcitriol -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 500 mg - suppository - excipient ingredients: hard fat - anaerobic infections: suppositories treatment of anaerobic infection in patients for whom oral medication is not possible or is contraindicated. prevention of anaerobic infection in high risk situations in patients for whom oral medication is not possible or is contraindicated. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia. note. metronidazole is inactive against aerobic and facultative anaerobic bacteria.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dksh agrisolutions pty ltd - petroleum oil - emulsifiable concentrate - petroleum oil petroleum derivative-oil active 859.0 g/l - adjuvant - cereals | fallow maintenance & conservation tillag | legume | pasture | bean | bean sprout | high intensity usage | other sprout - additive - refer to label

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

heiniger australia pty ltd - ortho-dichlorobenzene; liquid hydrocarbon - topical spray & lotion - ortho-dichlorobenzene benzene other 83.6 g/l; liquid hydrocarbon solvent other 383.9 g/l - branding substance - sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - dye marker

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

heiniger australia pty ltd - ortho-dichlorobenzene; liquid hydrocarbon - topical solution/suspension - ortho-dichlorobenzene benzene other 142.0 g/l; liquid hydrocarbon solvent other 99.0 g/l - branding substance - sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - branding

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg;  ; bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.